美国研究人员日前发表报告称，他们的研究显示，常用的糖尿病药物二甲双胍能提高卵巢癌患者的生存率。
明尼苏达州梅奥诊所研究人员比较了61名服用二甲双胍的卵巢癌患者和178名未服用二甲双胍的卵巢癌患者的数据。他们发现，服用二甲双胍组患者的5年生存率为67%，而对照组患者的5年生存率为47%。如剔除身高体重指数、癌症严重程度、化疗方式、手术质量等因素的影响，服用二甲双胍组患者的5年生存率比对照组患者要高4倍。
相关研究报告本周发表在美国《癌症》杂志网络版上。研究负责人桑吉夫·库马尔表示，研究结果“令人鼓舞”，但由于研究中有很多因素不可控，二甲双胍与卵巢癌患者生存率的提高是否具有直接关系仍不能下定论。库马尔表示，卵巢癌是一种死亡率很高的癌症，找到治疗卵巢癌的有效方式非常迫切，他们的研究可望为二甲双胍应用于卵巢癌治疗临床研究铺平道路。
二甲双胍是一种具有长期用药安全记录的药品。此前曾有研究显示，二甲双胍可以抑制肺部和乳腺肿瘤的生长，降低糖尿病患者患乳腺癌的风险。
Metformin intake is associated with better survival in ovarian cancer
Sanjeev Kumar MBBS, Alexandra Meuter MD, Prabin Thapa MS, Carrie Langstraat MD, Shailendra Giri PhD, Jeremy Chien PhD, Ramandeep Rattan PhD, William Cliby MD, Viji Shridhar PhD
BACKGROUND: The objective of this case-control study was to identify any association of metformin intake with the survival of patients with ovarian cancer.
METHODS: In this retrospective case-control study, women with ovarian cancer who received metformin (cases) were compared with women with ovarian cancer who did not receive metformin (controls). A 2-layered analysis was conducted. In preliminary analysis, all cases (the OC cohort) were compared with controls at a 1:2 ratio. Subsequently, in definitive analysis, only patients who had epithelial ovarian cancer (the EOC cohort) were compared with controls at a 1:3 ratio. In the EOC cohort, cases were matched with controls for age (±5 years), International Federation of Gynecology and Obstetrics stage, and residual disease. Prognostic variables and disease specific survival were compared using chi-square tests, the Kaplan-Meier (log-rank) method, and Cox proportional hazards analysis.
RESULTS: In a preliminary analysis of the OC cohort (72 cases and 143 controls), cases had better survival (5-year disease-specific survival for cases vs controls, 73% vs 44%; P = .0002). In the definitive analysis of the EOC cohort (61 cases and 178 controls), the distribution of age, disease stage, optimal cytoreduction, serous histology, and platinum chemotherapy remained similar between cases and controls (P > .05). Despite these similarities, cases had significantly better survival (5-year disease-specific survival for cases vs controls, 67% vs 47%; P = .007). On multivariate analysis, metformin remained an independent predictor of survival (hazard ratio, 2.2; 95% confidence interval, 1.2-3.8; P = .007) after controlling for disease stage, grade, histology, chemotherapy, body mass index, and surgical cytoreduction.
CONCLUSIONS: The results of this study indicated an association of metformin intake with survival in patients with ovarian cancer. The receipt of metformin was associated with better survival, and the authors concluded that metformin is worthy of clinical trials in ovarian cancer. Cancer 2012. © 2012 American Cancer Society.
文献链接：Metformin intake is associated with better survival in ovarian cancer
